Lantheus reports Q3 2026 results; FDA approves TAUKLARIFY and BRAVNETSA.

Lantheus reported worldwide revenue of $389.9 million and GAAP EPS of $0.33 for Q3 2026. Concurrently, the FDA approved TAUKLARIFY for tau PET imaging and granted final approval to BRAVNETSA for neuroendocrine tumors. The company recently agreed to be acquired by Curium.